Collectively, increased MET and AKT was correlated with rituximab resistance of DLBCL, which was consistent with our results that the phosphorylation level of AKT was elevated upon lncRNA CHROMR overexpression. The gene discussed is MET; the disease is diffuse large B-cell lymphoma.